QNTM
Quantum BioPharma Ltd.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · CA
$3.24
+9.83%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- +11.9%
- EBIT
- +89.8%
- EPS
- +71.7%
- Free cash flow
- +48.4%
- Operating cash flow
- +48.4%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- +77.9%
Three-year CAGR
- Revenue
- —
- EBITDA
- -79.4%
- EBIT
- +5.2%
- Net income
- -84.3%
- EPS
- +35.1%
- Free cash flow
- -21.9%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Jun 1, 2026